Reuters logo
BRIEF-Minerva Neuro announces positive results from phase IIB trial of MIN-101 monotherapy in schizophrenia
May 26, 2016 / 12:22 PM / a year ago

BRIEF-Minerva Neuro announces positive results from phase IIB trial of MIN-101 monotherapy in schizophrenia

May 26 (Reuters) - Minerva Neurosciences Inc

* Minerva neurosciences announces positive results from phase IIB trial of min-101 monotherapy in schizophrenia

* Statistically significant improvement in panss negative symptoms and total panss scores observed

* Says min-101 shown to be statistically superior on key secondary endpoints

* Says effect of min-101 demonstrated to be specific for negative symptoms and not secondary to improvement in other symptoms

* Says study successfully achieved its primary endpoint

* Says min-101 generally reported to be well tolerated, incidence, types of side effects did not differ significantly between min-101 group, placebo

* Says believe that min-101 may be a candidate for potential treatment of other indications in addition to schizophrenia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below